



“Construir o Futuro com a Ciência”

DOENÇA HEPÁTICA METABÓLICA: UMA QUESTÃO DE VIDA OU MORTE

Marta B. Afonso, PhD, PharmD

Investigadora Junior



*Instituto de Investigação do Medicamento,
Faculdade de Farmácia da Universidade de Lisboa*

Maio 2022

INTRODUCTION

NATURAL HISTORY OF NAFLD

NAFLD impacts ~25%
of the global adult
population




6th most common CANCER
3rd leading cause of CANCER DEATH


Strategies to slow the growth of NAFLD cases and therapeutic options are necessary to mitigate disease burden.





INTRODUCTION NAFLD PATHOGENESIS




Apoptosis




Necroptosis



AIMS & METHODS




In patients




NAFLD patients

2 independent cohorts


In vivo





In vitro



NAFLD patients













In vivo




RESULTS

RIPK3 ACTS AS A LIPID METABOLISM REGULATOR

Metabolic clustering



CONCLUSIONS



RIPK3 plays a key role in managing liver metabolism, damage, inflammation, fibrosis and carcinogenesis, whereby RIPK3 inhibition may ameliorate NAFLD.

Brito et al. *Cell Death Discovery* (2020)6:6
<https://doi.org/10.1038/s41420-020-0240-0>

Cell Death Discovery

ARTICLE

Open Access

Phenotypic high-throughput screening platform identifies novel chemotypes for necroptosis inhibition

Hugo Brito¹, Vanda Marques¹, Marta B. Afonso¹, Dean G. Brown², Ulf Börjesson³, Nidhal Selmi³, David M. Smith⁴, Ieuan O. Roberts⁵, Martina Fitzek⁶, Natália Aniceto¹, Rita C. Guedes¹, Rui Moreira¹ and Cecília M. P. Rodrigues¹

AstraZeneca



ACKNOWLEDGEMENTS



IMED.ULISBOA, FACULTY OF PHARMACY, UNIVERSIDADE DE LISBOA, PORTUGAL

Tawhidul Islam
Cecília M. P. Rodrigues

Rui E. Castro

Liana C. Silva

Maria M. Gaspar



CNC, UC BIOTECH BUILDING, UNIVERSIDADE DE COIMBRA, PORTUGAL

Ricardo Amorim,
Rui F. Simões
Paulo J. Oliveira



INSERM, PARIS, FRANCE

Jérémie Gautheron
Vlad Ratziu
Carina Prip-Buus



BIODOSNOSTIA, SAN SEBASTIAN, SPAIN

Jésus Banales
Pedro M. Rodrigues



FUNDING:

EU H2020 Marie Skłodowska-Curie (722619), FEDER (LISBOA-01-0145-FEDER-029097), FCT (PTDC/MED-FAR/29097/2017; UIDB/04539/2020), Fondation pour la Recherche Médicale (ARF20170938613 & EQU202003010517), Mairie de Paris (Emergences – R18139DD).

